Diagnostic Accuracy of a New Cardiac Electrical Biomarker for Detection of Electrocardiogram Changes Suggestive of Acute Myocardial Ischemic Injury

Objective A new cardiac “electrical” biomarker (CEB) for detection of 12‐lead electrocardiogram (ECG) changes indicative of acute myocardial ischemic injury has been identified. Objective was to test CEB diagnostic accuracy. Methods This is a blinded, observational retrospective case‐control, noninf...

Full description

Saved in:
Bibliographic Details
Published inAnnals of noninvasive electrocardiology Vol. 19; no. 2; pp. 129 - 144
Main Authors Schreck, David M., Fishberg, Robert D.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.03.2014
John Wiley & Sons, Inc
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN1082-720X
1542-474X
1542-474X
DOI10.1111/anec.12109

Cover

More Information
Summary:Objective A new cardiac “electrical” biomarker (CEB) for detection of 12‐lead electrocardiogram (ECG) changes indicative of acute myocardial ischemic injury has been identified. Objective was to test CEB diagnostic accuracy. Methods This is a blinded, observational retrospective case‐control, noninferiority study. A total of 508 ECGs obtained from archived digital databases were interpreted by cardiologist and emergency physician (EP) blinded reference standards for presence of acute myocardial ischemic injury. CEB was constructed from three ECG cardiac monitoring leads using nonlinear modeling. Comparative active controls included ST voltage changes (J‐point, ST area under curve) and a computerized ECG interpretive algorithm (ECGI). Training set of 141 ECGs identified CEB cutoffs by receiver‐operating‐characteristic (ROC) analysis. Test set of 367 ECGs was analyzed for validation. Poor‐quality ECGs were excluded. Sensitivity, specificity, and negative and positive predictive values were calculated with 95% confidence intervals. Adjudication was performed by consensus. Results CEB demonstrated noninferiority to all active controls by hypothesis testing. CEB adjudication demonstrated 85.3–94.4% sensitivity, 92.5–93.0% specificity, 93.8–98.6% negative predictive value, and 74.6–83.5% positive predictive value. CEB was superior against all active controls in EP analysis, and against ST area under curve and ECGI by cardiologist. Conclusion CEB detects acute myocardial ischemic injury with high diagnostic accuracy. CEB is instantly constructed from three ECG leads on the cardiac monitor and displayed instantly allowing immediate cost‐effective identification of patients with acute ischemic injury during cardiac rhythm monitoring.
Bibliography:istex:CA455FD12F4A2E2FBBAB8C192A0D6A5B8F5D0894
ark:/67375/WNG-PRXJSHV1-3
ArticleID:ANEC12109
Funding Sources/Disclosures
Awards
Portions of this study were presented at the Society for Critical Care Medicine 40th Annual Critical Care Congress, San Diego, California, January 16, 2011, for which it won the first place research award.
Annual Scientific Sessions, May 7, 1996, Denver, Colorado, for which it won first prize as the Best Technology Presentation.
Dr. David M. Schreck owns a significant nonmajority interest in VectraCor that constitutes greater than 5% of the entity. VectraCor is the medical device company that has developed the technology for the derivation of the n‐lead ECG and the cardiac electrical biomarker.
Portions of the this study were presented at the Society for Academic Emergency Medicine
This study was unfunded.
Portions of this study were presented at the American College of Emergency Physicians Scientific Assembly September 14–16, 1992, Seattle, Washington, for which it received first prize award for the Best Educational Exhibit.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1082-720X
1542-474X
1542-474X
DOI:10.1111/anec.12109